Key Takeaways:
Vertex Pharmaceuticals won FDA approval for CASGEVY gene therapy in children as young as 2 with sickle cell disease or transfusion-dependent beta thalassemia, the first genetic treatment cleared for this age group.
"CASGEVY is now the first approved genetic therapy indicated for children as young as 2 for both sickle cell disease and transfusion-dependent beta thalassemia," Vertex said in a statement.
The expanded approval covers patients aged 2 years and older with sickle cell disease who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. CASGEVY, a one-time treatment made from a patient's own blood stem cells, was previously approved for patients aged 12 and older with either condition.
In a trial of children aged 5 to under 12 with sickle cell disease, all eight evaluable patients had no severe vaso-occlusive crises for at least 12 straight months within the first 24 months of infusion. Among children with beta thalassemia, eight of nine evaluable patients achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months.
The FDA granted the expanded approval 53 days after Vertex filed under the Commissioner's National Priority Voucher, a fast-track program designed to shorten review time for drug applications. The agency had previously approved CASGEVY for patients aged 12 and older in 2023, alongside a gene therapy from Genetix Biotherapeutics.
Other long-term treatment options for sickle cell disease include bone marrow transplant, which requires matching donors, and the chemotherapy drug hydroxyurea.
The expanded approval significantly broadens Vertex's addressable patient population for CASGEVY, adding children aged 2 to 11 to the eligible pool. Investors will watch for updated revenue guidance from Vertex on its next earnings call for initial prescription trends in the younger age group.
This article is for informational purposes only and does not constitute investment advice.
